Biomarker and Tissue Support for Glioblastoma Care
Biomarker, Bioinformatics and Biorepository Core
This program builds the lab tests, data analysis, and tissue bank needed to bring a new drug called 6-thio-dG to people with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11164686 on NIH RePORTER |
What this research studies
From a patient viewpoint, the core will standardize how tumor tissue is collected, reviewed, and stored across participating centers so results are consistent. It will run CLIA-approved tests on tumor genes like IDH1/2 and TERT to help decide who can receive 6-thio-dG and provide central neuropathology review. The team will measure markers of drug activity, such as DNA damage, after treatment and handle the bioinformatics and biostatistics to interpret those results. These services will be shared across the Duke/UT Southwestern network to support the early-phase clinical work.
Who could benefit from this research
Good fit: Adults with glioblastoma whose tumors meet the molecular and clinical eligibility criteria (for example based on IDH1/2 or TERT status) and who can undergo the trial procedures are ideal candidates.
Not a fit: People without glioblastoma, those whose tumors lack the required genetic features, or those too young or medically unable to undergo required surgeries or tissue collection are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this could speed safe testing of 6-thio-dG and help identify which glioblastoma patients are most likely to benefit.
How similar studies have performed: Telomere-targeting agents like 6-thio-dG have shown promise in laboratory and animal studies, but human testing of this specific approach is just beginning.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Mclendon, Roger E — Duke University
- Study coordinator: Mclendon, Roger E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.